P-191: Association of STK11 Gene Polymorphisms with Methformin Treatment in Patients with Polycystic Ovary Syndrome

Background: Metformin is an insulin sensitizing drug, which is co-administered with Clominophene citrate or gonadotropins in most cases of polycystic ovary syndrome (PCOS), to improve ovulation. STK11 gene is necessary for action of metformin. Therefore the study of STK11 polymorphisms is important as pharmacogenetics aspects of metformin. The aim of our study was to investigate polymorphism of STK11 gene in PCOS patients (40 people) in comparison to 2 other groups used as fertile (40 people) and drug response-control (40 people) groups to clarify whether any differences between three groups exists in observed single nucleotide polymorphisms (SNPs). Materials and Methods: Multiple polymorphisms of STK11 were examined on DNA isolated from blood samples. In exons 6, 8 we used Polymerase chain reactionrestriction fragment length polymorphism (PCR- RFLP) while sequencing was undertaken to study exon 4, introns 1and 3 to detect known SNPs. Two amino acids of active site in exon 4 were also studied. Results: The results indicated that polymorphism in intron 1 of STK11 was associated with PCOS.The highest percentage of individuals with GG genotype (37.5%) was in PCOS group. Individuals with this genotype had high insulin level and showed better response to treatment with metformin. Our fertile control group has showed 7.5% of GG genotype. Conclusion: In total, 40% (48 out of 120) of our studied population, were shown SNP (rs2075606) (T>C) in intron 3. Data showed SNPs of exons 4, 6, 8 were not associated with PCOS. No amino acid change was observed in active site of this gene.